Nexium Iv Patent Expiration

Nexium Iv is a drug owned by Astrazeneca Pharmaceuticals Lp. It is protected by 3 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 04, 2017. Details of Nexium Iv's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5877192

(Pediatric)

Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
Nov, 2014

(10 years ago)

Expired
US5877192 Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
May, 2014

(10 years ago)

Expired
US6143771 Compounds
May, 2014

(10 years ago)

Expired


FDA has granted several exclusivities to Nexium Iv. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Nexium Iv, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Nexium Iv.

Exclusivity Information

Nexium Iv holds 2 exclusivities. All of its exclusivities have expired in 2017. Details of Nexium Iv's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-138) Mar 04, 2017
New Indication(I-679) Mar 04, 2017

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Nexium Iv is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Nexium Iv's family patents as well as insights into ongoing legal events on those patents.

Nexium Iv's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Nexium Iv's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Mar 04, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Nexium Iv Generic API suppliers:

Esomeprazole Sodium is the generic name for the brand Nexium Iv. 7 different companies have already filed for the generic of Nexium Iv, with Gland Pharma Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Nexium Iv's generic

How can I launch a generic of Nexium Iv before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Nexium Iv's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Nexium Iv's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Nexium Iv -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
20 mg/vial and 40 mg/vial 23 Nov, 2009 1 18 Mar, 2013 27 May, 2014 Deferred





About Nexium Iv

Nexium Iv is a drug owned by Astrazeneca Pharmaceuticals Lp. It is used for short-term treatment of gastroesophageal reflux disease (GERD) when oral therapy with Nexium capsules is not possible or appropriate. Nexium Iv uses Esomeprazole Sodium as an active ingredient. Nexium Iv was launched by Astrazeneca in 2005.

Approval Date:

Nexium Iv was approved by FDA for market use on 31 March, 2005.

Active Ingredient:

Nexium Iv uses Esomeprazole Sodium as the active ingredient. Check out other Drugs and Companies using Esomeprazole Sodium ingredient

Treatment:

Nexium Iv is used for short-term treatment of gastroesophageal reflux disease (GERD) when oral therapy with Nexium capsules is not possible or appropriate.

Dosage:

Nexium Iv is available in injectable form for intravenous use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 20MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** INJECTABLE Discontinued INTRAVENOUS
EQ 40MG BASE/VIAL INJECTABLE Discontinued INTRAVENOUS